Robert Y Wilpan
YOU?
Author Swipe
View article: Dystonin modifiers of junctional epidermolysis bullosa and models of epidermolysis bullosa simplex without dystonia musculorum
Dystonin modifiers of junctional epidermolysis bullosa and models of epidermolysis bullosa simplex without dystonia musculorum Open
The Lamc2 jeb junctional epidermolysis bullosa (EB) mouse model has been used to demonstrate that significant genetic modification of EB symptoms is possible, identifying as modifiers Col17a1 and six other quantitative trait loci, several …
View article: Functional analysis of Collagen 17a1: A genetic modifier of junctional epidermolysis bullosa in mice
Functional analysis of Collagen 17a1: A genetic modifier of junctional epidermolysis bullosa in mice Open
Previous work strongly implicated Collagen 17a1 ( Col17a1 ) as a potent genetic modifier of junctional epidermolysis bullosa (JEB) caused by a hypomorphic mutation ( Lamc2 jeb ) in mice. The importance of the noncollagenous domain (NC4) of…
View article: Application of 4-D ultrasound-derived regional strain and proteomics analysis in <i>Nkx2-5</i>-deficient male mice
Application of 4-D ultrasound-derived regional strain and proteomics analysis in <i>Nkx2-5</i>-deficient male mice Open
A multimodal approach using both four-dimensional ultrasound (4DUS) and regional proteomics can help enhance our investigations of murine cardiomyopathy models. We present unique 4DUS-derived strain maps that provide a framework for both c…
View article: Data from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes
Data from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes Open
Molecular cancer diagnostics are an important clinical advance in cancer management, but new methods are still needed. In this context, gene expression signatures obtained by microarray represent a useful molecular diagnostic. Here, we des…
View article: Supplementary Methods, Figures 1-10, Tables 1-19 from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes
Supplementary Methods, Figures 1-10, Tables 1-19 from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes Open
Supplementary Methods, Figures 1-10, Tables 1-19 from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes
View article: Supplementary Methods, Figures 1-10, Tables 1-19 from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes
Supplementary Methods, Figures 1-10, Tables 1-19 from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes Open
Supplementary Methods, Figures 1-10, Tables 1-19 from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes
View article: Data from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes
Data from Global Changes in Processing of mRNA 3′ Untranslated Regions Characterize Clinically Distinct Cancer Subtypes Open
Molecular cancer diagnostics are an important clinical advance in cancer management, but new methods are still needed. In this context, gene expression signatures obtained by microarray represent a useful molecular diagnostic. Here, we des…